可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]胡大一,高润霖,葛均波,等.心血管疾病防治指南和共识2010[M].北京:人民卫生出版社,2010:20-21.
[2]金彦彦,马长生.不同年龄段急性冠状动脉综合征患者的危险因素、冠状动脉病变特点及预后分析[J].中国介入心脏病学杂志,2009,17(1):28-31.
[3]Grobbee DE.Statin treatment and progression of atherosclerotic plaque burden[J].Drugs,2003,63(9):893-911.
[4]Rosenson RS.Statins in atherosclerosis:lipid-lowering agents with antioxidant capabilities[J].Atherosclerosis,2004, 173(1):1-12.
[5]康俊萍,马长生.非ST段抬高和ST段抬高心肌梗死患者介入结果的比较[J].中华急诊医学杂志,2010,20(19):11-25.
[6]胡大一,高润霖,葛均波,等.心血管疾病防治指南和共识2011[M].北京: 人民卫生出版社,2011:177-178.
[7]Morishi I,Sone T,Okumura K,et al.Agiographic no reflow phenomenon as a predictor of adverse long term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction[J].JACC,2000,36(6):1202-1209.
[8]Tanaka A,Kawarahayashi T,Nishibori Y,et al.No reflow phenomenon and lesion morphology in patiens with acute myocardial infarction[J].Ciuculation,2001,105(6):2148-2152.
[9]陈纪林.冠心病介入治疗并发症的防治[M].北京:人民卫生出版社,2010:44-53.
[10]Gurm H,Tamhane U, Meier P,et al.A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials[J].Ciuculation,2009,2(3):230-236.
[11]Gibson CM,Cannon CP, Murphy SA,et al.Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs[J].Circulation,2000,101(2):125-130.
[12]陈纪林.冠心病介入治疗并发症的防治[M].北京:人民卫生出版社,2010:96-98.